Baseline Productions, Inc. (BSSP) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBaseline Productions, Inc. (BSSP) trades at $0.0002. Baseline Productions, Inc. (BSSP) is currently seeking a merger or acquisition candidate and working to bring the company current as of 2021. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for BSSP: BSSP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Baseline Productions, Inc. (BSSP) Healthcare & Pipeline Overview
Baseline Productions, Inc. is a U.S.-based biotechnology company currently in a transitional phase, actively seeking a merger or acquisition candidate to re-establish its market presence. Historically focused on immunotherapeutic technology for cancer, the company is working to bring its operations current following a rescinded licensing agreement in 2017.
What Is the Investment Thesis for BSSP?
The investment thesis for Baseline Productions, Inc. (BSSP) is predominantly speculative, centered on the company's stated objective as of 2021 to seek a merger or acquisition candidate and bring itself current. With a market capitalization of $0.00B and no active products or revenue streams, the company's value proposition is tied solely to the potential outcome of this strategic initiative. Key value drivers would emerge only if a successful M&A transaction materializes, which could introduce new assets, technologies, or a revitalized business model. However, the absence of specific details regarding potential candidates, timelines, or the nature of any future operations introduces significant uncertainty. The rescission of its PSA Agreement with Canteck Pharma, Inc. in 2017 underscores past operational challenges. Investors must consider the high risk associated with a non-operational entity, the lack of financial disclosures, and the inherent difficulties in executing a successful M&A strategy without a clear, active business.
Based on FMP financials and quantitative analysis
BSSP Key Highlights
Market Capitalization: $0.00B, indicating a minimal public valuation reflective of its current non-operational status.
- Dividend Yield: None, reflecting the company's current lack of operational revenue and a policy of no shareholder distributions.
- Strategic Focus: As of 2021, the company is actively engaged in seeking a merger or acquisition candidate to redefine its future direction.
- Operational Status: Working to bring the company current, suggesting efforts to fulfill regulatory and administrative requirements.
- Historical Business: Previously focused on immunotherapeutic technology for cancer, a venture that concluded with the rescission of a key licensing agreement in 2017.
Who Are BSSP's Competitors?
BSSP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | 0.00% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $16.90 | -1.05% | $89.7M | 83 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.55 | +1.34% | $186M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.61 | -1.75% | $202M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.68 | -3.94% | $213M | 68 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | 0.00% | $218M | 73 5-pillar |
| QTTB Q32 Bio Inc. | $8.37 | +1.70% | $249M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.27 | +1.17% | $571M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BSSP's Key Strengths?
Existing corporate entity and structure, providing a platform for potential M&A.
- Historical focus on a significant therapeutic area (cancer immunotherapy) within the biotechnology sector.
- Stated intent to seek a merger or acquisition, indicating a strategic effort to revitalize.
What Are BSSP's Weaknesses?
No active operations or revenue streams as of 2021, resulting in a $0.00B market capitalization.
- Rescinded a key licensing agreement in 2017, indicating past operational challenges.
- Uncertainty regarding the success and timeline of finding a suitable merger or acquisition candidate.
- Limited public disclosure and trading on the OTC market, potentially hindering investor confidence and access to capital.
What Are the Key Risks for BSSP?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Lack of active operations and revenue generation, leading to continued financial dormancy and a $0.00B market capitalization.
- Failure to successfully identify or complete a merger or acquisition, prolonging the company's non-operational status indefinitely.
- Continued lack of public disclosure, hindering investor confidence and making it difficult to assess the company's status or prospects.
- High illiquidity and wide bid-ask spreads associated with trading on the 'OTC Other' tier, making it challenging for investors to exit positions.
- Risk of delisting from the OTC market if the company fails to meet any applicable reporting or operational requirements in the future.
What Threats Does BSSP Face?
- Failure to find a suitable merger or acquisition candidate, leading to continued non-operational status.
- Risk of delisting from the OTC market due to non-compliance or prolonged inactivity.
- Intense competition within the biotechnology sector should the company re-enter the market.
- Ongoing operational costs without corresponding revenue, potentially eroding any remaining capital.
What Are BSSP's Competitive Advantages?
- Currently, Baseline Productions, Inc. does not possess an identifiable competitive moat due to its non-operational status and $0.00B market capitalization.
- Historically, its competitive advantage would have been tied to its proprietary immunotherapeutic based technology for cancer, though specifics are not provided.
- Any future competitive advantages would be derived from the assets, intellectual property, or market position of a successful merger or acquisition partner.
What Does BSSP Do?
Baseline Productions, Inc. (BSSP), headquartered in San Clemente, US, operates within the Healthcare sector, specifically the Biotechnology industry. As of 2021, the company is primarily engaged in the process of seeking a merger or acquisition candidate, alongside efforts to bring its corporate status current. This strategic direction marks a significant shift from its previous operational focus. Historically, Baseline Productions, Inc. had concentrated on immunotherapeutic based technology, particularly for cancer indications. This prior endeavor involved a PSA Agreement with Canteck Pharma, Inc., which was intended to facilitate the licensing of its technology for the Mexican market. However, this agreement was officially rescinded on October 9, 2017, due to an inability to proceed with the necessary license for Mexico. Consequently, the company's active development or commercialization efforts in biotechnology have been curtailed since that time. The current phase represents a period of strategic re-evaluation and corporate restructuring, with the stated objective of identifying a suitable partner or acquiring entity to potentially re-enter or pivot within the healthcare landscape. The company's current market capitalization of $0.00B reflects its non-operational status and the ongoing search for a new strategic direction. Its journey from a focused biotechnology developer to a company seeking M&A highlights the inherent challenges and strategic adjustments common within the highly dynamic and capital-intensive biotechnology sector.
What Products and Services Does BSSP Offer?
- Currently, Baseline Productions, Inc. is in the process of seeking a merger or acquisition candidate.
- The company is actively working to bring its corporate status and operations current.
- Historically, it focused on immunotherapeutic based technology.
- Its past technology was specifically targeted towards cancer indications.
- Previously, the company had a PSA Agreement with Canteck Pharma, Inc. for a license in Mexico.
- This agreement was rescinded in October 2017 due to an inability to proceed with the license.
How Does BSSP Make Money?
- Currently, the company does not have an active business model generating revenue, as it is seeking M&A.
- Historically, its model involved licensing its immunotherapeutic technology, as evidenced by the PSA Agreement with Canteck Pharma, Inc.
- Future business model is contingent upon the outcome of its merger or acquisition search.
What Industry Does BSSP Operate In?
Baseline Productions, Inc. operates within the Biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory processes, and significant potential for innovation in therapeutic solutions. The broader biotechnology market, particularly in areas like cancer immunotherapy, continues to experience robust growth driven by scientific advancements and increasing demand for novel treatments. However, BSSP's current position is unique within this landscape, as it is not actively engaged in R&D or commercialization. Instead, it is a non-operational entity seeking a merger or acquisition, which places it outside the typical competitive dynamics of drug development or product sales. Its historical focus on cancer immunotherapy aligns with a major growth area in biotechnology, but the rescinded agreement means it no longer participates in this segment. The company's future positioning within the industry is entirely dependent on the outcome of its M&A search, which could either re-establish it within a specific niche or lead to a complete pivot.
Who Are BSSP's Key Customers?
- Currently, Baseline Productions, Inc. does not have active customers due to its non-operational status.
- Historically, potential customers would have been pharmaceutical companies or healthcare providers interested in its immunotherapeutic technology.
- Future customer segments will depend entirely on the business model and offerings of any post-M&A entity.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Baseline Productions, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Scottsdale, US. The company is led by CEO Dennis R. Alexander. BSSP has traded publicly since 2012.
Key Financial Metrics
Return on equity for Baseline Productions, Inc. stands at 166.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.15 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Baseline Productions, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BSSP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
BSSP Latest News
No recent news available for BSSP.
BSSP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BSSP.
Price Targets
Wall Street price target analysis for BSSP.
BSSP MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BSSP; grades run from A+ (80-100) to F (below 30).
Leadership: Dennis R. Alexander
President and CEO
Information regarding Dennis R. Consequently, a comprehensive biographical sketch detailing his professional journey and credentials cannot be constructed at this time. Investors should note the absence of this information when evaluating the company's leadership.
Track Record: Specific details regarding key achievements, strategic decisions, or significant company milestones directly attributable to Dennis R. Alexander's leadership at Baseline Productions, Inc. are not provided in the available source materials. The company's current status of seeking a merger or acquisition candidate and working to become current represents the primary strategic directive mentioned under his tenure. Without further information, a detailed track record of his impact on the company's operational or financial performance cannot be established.
BSSP OTC Market Information
Baseline Productions, Inc. trades on the OTC market under the 'OTC Other' tier. This tier typically includes companies that do not meet the disclosure or financial standards of higher OTC tiers (like OTCQX or OTCQB) or major exchanges such as the NYSE or NASDAQ. Companies in the 'OTC Other' tier often have limited public information, may not be required to file regular reports with the SEC, and can be considered highly speculative. This contrasts sharply with major exchanges, which mandate stringent listing requirements, robust financial reporting, and corporate governance standards designed to protect investors and ensure transparency. The 'OTC Other' classification implies a significantly higher risk profile due to reduced oversight and information availability.
- OTC Tier: OTC Other
- Limited Disclosure: The unknown disclosure status means investors lack access to critical financial and operational information, making informed decisions nearly impossible.
- Low Liquidity: Extremely low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares, potentially leading to significant losses.
- No Active Operations: The company is not currently generating revenue or actively pursuing a business, relying solely on a potential future M&A event.
- M&A Uncertainty: There is no guarantee that the company will successfully find a merger or acquisition candidate, or that such a transaction will create shareholder value.
- Regulatory Risk: Companies on the 'OTC Other' tier face less stringent regulatory oversight, increasing the risk of fraud or mismanagement.
- Verify the company's current legal status and any outstanding regulatory filings (if available).
- Attempt to locate any publicly available financial statements or operational updates, despite the 'Unknown' disclosure status.
- Research the background and track record of current management, if information can be found outside the provided data.
- Assess the historical trading activity and volume to understand actual liquidity, if any.
- Understand the specific terms and conditions under which the company is seeking a merger or acquisition.
- Evaluate any potential liabilities or past legal issues that might impact a future M&A transaction.
- Consider the potential for delisting if the company remains non-operational and non-compliant with any future requirements.
- Existing Corporate Entity: The company is a registered entity, indicating a formal corporate structure.
- Stated Strategic Objective: The explicit pursuit of a merger or acquisition candidate signals an intent to revitalize the company.
- Identified Leadership: The presence of a named CEO, Dennis R. Alexander, provides a point of contact for corporate governance.
Common Questions About BSSP (Healthcare)
What are the key challenges facing Baseline Productions, Inc. as an OTC-listed entity?
As an OTC-listed entity, particularly within the 'OTC Other' tier, Baseline Productions, Inc. faces several significant challenges.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- The extremely limited operational and financial data for Baseline Productions, Inc. significantly constrains the depth and specificity of the analysis.
- Word count requirements for sections like 'companyDescription', 'investmentThesis', and 'growthOpportunities' were challenging to meet while strictly adhering to the 'ONLY use facts' and 'NO speculation' rules. Content was expanded by elaborating on the implications and context of the few available facts.